已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

803-P: Superior Glycemic Control with Once-Weekly Insulin Icodec with a Dosing Guide App vs. Once-Daily (OD) Basal Insulin Analogs in Insulin-Naïve T2D—ONWARDS 5

作者
HARPREET SINGH BAJAJ,Jens Aberle,Melanie Jane Davies,Anders Meller Donatsky,MARIE FREDERIKSEN,Dilek Gogaş Yavuz,Amoolya Gowda,ILDIKO LINGVAY,Bruce W. Bode
出处
期刊:Diabetes [American Diabetes Association]
卷期号:72 (Supplement_1) 被引量:1
标识
DOI:10.2337/db23-803-p
摘要

ONWARDS 5 (NCT04760626), a 52-week, open-label, randomized, phase 3a trial with real-world elements, assessed effectiveness and safety of once-weekly insulin icodec with a dosing guide app (icodec) vs OD basal insulin analogs (degludec, glargine U100 or glargine U300) in insulin-naïve adults with T2D. Participants (mean: 59.3 yrs; 32.8 kg/m2) were randomized 1:1 to icodec or OD analogs. The dose guidance app aided icodec titration; OD analogs were titrated as per standard of care. Estimated mean A1C change from baseline (BL) to week 52 was greater with icodec (-1.68%-points, BL 9.0%) vs OD analogs (-1.31%-points, BL 8.9%) confirming non-inferiority (p<0.0001) and superiority (p=0.009) of icodec vs OD analogs. Patient-reported outcomes (DTSQ and TRIM-D) were statistically significant in favor of icodec vs OD analogs at week 52. Rates of level 2 (<54 mg/dL) or level 3 (severe) hypoglycemia were low for both treatments (0.19 [icodec] vs 0.14 [OD analogs] events per person-year of exposure). There were no significant differences between treatments in time to treatment discontinuation/intensification. Overall, icodec with a dosing guide app showed superiority in A1C reduction, and significant improvement in treatment satisfaction and compliance scores vs OD analogs, with low hypoglycemia rates, in insulin-naïve adults with T2D in a real-world setting. Disclosure H.S.Bajaj: Research Support; Amgen Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Anji Pharmaceuticals, Eli Lilly and Company, Kowa Company, Ltd., Novo Nordisk, Pfizer Inc., Sanofi, Tricida, Inc. J.Aberle: Advisory Panel; Novo Nordisk, Speaker's Bureau; Novo Nordisk. M.J.Davies: Advisory Panel; Lilly, Boehringer-Ingelheim, Novo Nordisk, Sanofi, Lexicon Pharmaceuticals, Inc., Pfizer Inc., Medtronic, ShouTi Pharma Inc., Consultant; Lilly, Boehringer-Ingelheim, Novo Nordisk, Sanofi, Research Support; AstraZeneca, Novo Nordisk, Sanofi-Aventis U.S., Boehringer-Ingelheim, Janssen Pharmaceuticals, Inc., Speaker's Bureau; Lilly, Boehringer-Ingelheim, Novo Nordisk, AstraZeneca, Napp Pharmaceuticals Limited, Novartis, Sanofi. A.M.Donatsky: Employee; Novo Nordisk. M.Frederiksen: Employee; Novo Nordisk A/S. D.Gogas yavuz: Advisory Panel; Sanofi, Speaker's Bureau; Novo Nordisk, Boehringer-Ingelheim. A.Gowda: Employee; Novo Nordisk A/S. I.Lingvay: Advisory Panel; Novo Nordisk A/S, Lilly Diabetes, Boehringer-Ingelheim, Sanofi, Consultant; Carmot Therapeutics, Inc., Merck Sharp & Dohme Corp., Janssen Scientific Affairs, LLC, Pfizer Inc., Intercept, Intarcia, Valeritas, TargetRWE, Shionogi, Zealand Pharma, Structure, Bayer, Research Support; Novo Nordisk A/S, Boehringer-Ingelheim. B.W.Bode: Advisory Panel; Ascensia Diabetes Care, MannKind Corporation, Medtronic, Novo Nordisk, Zealand Pharma A/S, Research Support; Abbott Diabetes, Abvance Therapeutics, Better Therapeutics, Inc, Dexcom, Inc., Diasome, Dompé, Insulet Corporation, Lilly Diabetes, Medtronic, Novo Nordisk, Sanvita Medical, Senseonics, Provention Bio, Inc., REMD Biotherapeutics, ViaCyte, Inc., Xeris Pharmaceuticals, Inc., vTv Therapeutics, Speaker's Bureau; Abbott Diabetes, American Diabetes Association, Boehringer Ingelheim and Eli Lilly Alliance, Insulet Corporation, Lilly Diabetes, MannKind Corporation, Novo Nordisk, Sanofi, Xeris Pharmaceuticals, Inc., Stock/Shareholder; Glytec, LLC. Funding Novo Nordisk A/S

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科目三的应助被春晓采纳,获得10
刚刚
高大橙发布了新的文献求助10
刚刚
丘比特的应助被土豆采纳,获得10
刚刚
1秒前
huiyouzhiyu完成签到,获得积分10
2秒前
Orange的应助被kskfjs采纳,获得10
2秒前
hellolulu88完成签到,获得积分10
3秒前
cheng发布了新的文献求助10
3秒前
英姑的应助被胡图图采纳,获得10
3秒前
4秒前
Clarissa发布了新的文献求助10
5秒前
6秒前
车厘子发布了新的文献求助10
7秒前
vc发布了新的文献求助30
8秒前
9秒前
美满夏寒完成签到,获得积分10
9秒前
科研通AI6.3的应助被奋斗听筠采纳,获得10
9秒前
Kai完成签到,获得积分10
9秒前
10秒前
李健的应助被我是666采纳,获得10
10秒前
11秒前
小蘑菇的应助被潇洒的代双采纳,获得10
11秒前
11秒前
11秒前
侃侃完成签到,获得积分10
12秒前
12秒前
初景的应助被马浩然采纳,获得20
13秒前
13秒前
13秒前
13秒前
13秒前
14秒前
14秒前
wanci的应助被szxa采纳,获得10
14秒前
15秒前
16秒前
16秒前
胡图图发布了新的文献求助10
16秒前
mitolin发布了新的文献求助10
16秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179104
求助须知:如何正确求助?哪些是违规求助? 9569680
关于积分的说明 21806134
捐赠科研通 7774263
什么是DOI,文献DOI怎么找? 3433003
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478643